Endometrial Carcinoma Study
GOG 0249: A Phase III Trial of Pelvic Radiation Therapy versus Vaginal Cuff Brachytherapy followed by Paciltaxel/Carboplatin Chemotherapy in patients with High Risk, Early Stage Endometerial Carcinoma
Protocol ID
Protocol Description
The main purpose of this study is to compare the effects of radiation therapy to the pelvis with vaginal radiation therapy combined with three cycles of the chemotherapy drugs paclitaxel and carboplatin on high-risk Stage I-II endometrial cancer to find out which works better in reducing the chance that the cancer comes back. In this study, patients will receive either radiation therapy to the pelvis (standard of care) or vaginal radiation therapy combined with three cycles of the chemotherapy drugs paclitaxel and carboplatin (investigational). The pelvic radiation therapy (Regimen I) is what is usually done for patients with this disease and is considered standard of care. In addition, this study will compare survival, side effects, and differences in where the cancer may recur in patients treated with one of the two treatments. The study will also look at how a patient’s overall health and weight impact how well patients do and how these factors affect a patient’s quality of life. This study is also interested in testing samples of tumor tissue and blood to determine if this testing can be used in the future to determine which patients may respond to treatment or have a good prognosis.
Eligibility Criteria
Patients with advanced endometrial carcinoma
Primary Investigator(s)
- Veena John, MD